GlassScriptPhysician profile
Heather L Haley
NPI 1194947143
$5,895.96
in general payments reported to CMS, 2019-2025
36 companies · $911 in 2025
The $911 reported for 2025 was more than what 76% of Nephrology (Internal Medicine) providers received nationally (typical 2025 total: $311).
See the full distribution for Nephrology (Internal Medicine)
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,045 · 2020: $351 · 2021: $513 · 2022: $443 · 2023: $1,279 · 2024: $1,354 · 2025: $911.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $3,544.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $3,544.13 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astrazeneca Pharmaceuticals LP | $746.73 | 2019-2025 | Lokelma, Farxiga |
| Amgen INC. | $647.46 | 2019-2025 | Krystexxa, Tavneos, Parsabiv |
| Vifor Pharma, INC. | $554.13 | 2019-2023 | Veltassa |
| Fresenius USA Marketing, INC. | $524.24 | 2019-2025 | Velphoro, Velphoro |
| Bayer Healthcare Pharmaceuticals INC. | $343.45 | 2021-2025 | |
| Novartis Pharmaceuticals Corporation | $342.80 | 2023-2025 | |
| Otsuka America Pharmaceutical, INC. | $336.54 | 2019-2025 | Jynarque |
| Dermavant Sciences, INC. | $320.63 | 2022-2024 | Vtama |
| Glaxosmithkline, LLC. | $290.49 | 2020-2024 | Benlysta, Jesduvroq |
| Akebia Therapeutics INC | $193.97 | 2019-2024 | Vafseo, Auryxia |
| Alexion Pharmaceuticals, INC. | $172.77 | 2020-2025 | Ultomiris, Soliris |
| Mallinckrodt Hospital Products INC. | $156.22 | 2020-2025 | Terlivaz |
| Travere Therapeutics, INC. | $152.16 | 2019-2025 | |
| Opko Pharmaceuticals, LLC | $147.39 | 2019-2024 | Rayaldee |
| Ardelyx, INC. | $145.43 | 2024 | Xphozah 30 Mg, Ibsrela |
Show all 36 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Medtronic, INC. | $116.23 | 2025 | Symplicity G3 |
| Calliditas Therapeutics US INC. | $106.31 | 2023-2025 | Tarpeyo |
| Allergan, INC. | $82.16 | 2019 | |
| Xeris Pharmaceuticals, INC. | $69.39 | 2024 | Keveyis |
| Novo Nordisk INC | $53.31 | 2025 | Ozempic, Rybelsus |
| Horizon Therapeutics Plc | $51.80 | 2023 | Krystexxa |
| Lilly USA, LLC | $45.80 | 2024-2025 | Jardiance |
| Arcutis Biotherapeutics, INC. | $35.12 | 2024 | Zoryve |
| Daiichi Sankyo INC. | $34.60 | 2019-2021 | |
| Bard Peripheral Vascular, INC. | $31.53 | 2019 | |
| Ani Pharmaceuticals, INC. | $30.81 | 2024 | Purified Cortrophin Gel |
| Baxter Healthcare | $28.55 | 2020-2021 | |
| Nxstage Medical, INC. | $22.17 | 2023 | Nxstage System One, Liberty Select Cycler |
| Aurinia Pharma U.S., INC. | $18.70 | 2022 | |
| Mallinckrodt Enterprises LLC | $18.51 | 2019 | |
| Botanix Sb INC | $17.72 | 2025 | Sofdra |
| Otsuka Pharmaceutical Development & Commercialization, INC. | $15.68 | 2019 | |
| Abbvie INC. | $14.10 | 2021 | |
| Cycle Pharmaceuticals INC | $13.24 | 2024 | Tiopronin |
| Kyowa Kirin, INC. | $13.24 | 2023 | |
| Organon LLC | $2.58 | 2025 | Vtama |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Heather Haley listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.